submit to the journals

Atrial fibrillation Journal Articles, Videos And Insights

Atrial fibrillation: FEATURED Articles

flipper_slider

Atrial fibrillation: Latest Articles

Atrial fibrillation: INSIGHTS

The touchCARDIO website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of cardio:

Insight
Fewer Bleeding Complications with Uninterrupted Dabigatran Versus Warfarin for Ablation in Atrial Fibrillation Catherine Amey, Senior Medical Writer, Touch Medical Media, Reading, UK
Insight
Pacemaker Programme Reduces Dangerous Fainting Episodes in the SPAIN Study Catherine Amey, Senior Medical Writer, Touch Medical Media, Reading, UK
Insight
Left Atrial Appendage Occlusion Reduces Thromboembolism Risk in Patients with Atrial Fibrillation Catherine Amey, Senior Medical Writer, Touch Medical Media, Reading, UK
Insight
Larger Body Size in Women Increases Risk of Atrial Fibrillation Catherine Amey, Senior Medical Writer, Touch Medical Media, Reading, UK
Insight
Heightened Risk of Death for Patients with Atrial Fibrillation Taking Digoxin Catherine Amey, Senior Medical Writer, Touch Medical Media, Reading, UK

Atrial fibrillation: FEATURED VIDEOS

Editor's choice

Jose Merino gives an overview of the ENSURE-AT and EMANATE trials along with future studies planned for new oral anticoagulants (NOACs). Disclosures: Jose Merino has received consultory and speaker fees from Daiichi-Sankyo, Bayer, BMS, Boheringhe, Sanofi and Cardiome. FILMED AT THE CARDIOSTIM ANNUAL MEETING, JUNE 2016 WHAT ARE THE RISKS OF NEW ORAL ANTICOAGULANT USE IN PATIENTS UNDERGOING CARDIOVERSION? 00:11 – The use of NOACs for cardioversion is something that is really appealing because it’s a very easy to manage treatment. The problem is that we presently don’t know if they are as effective as warfarin in order to prevent clots formation after cardioversion. And at the same time, safety is also an issue that needs to be proven if these agents are safer than warfarin and enoxaparin, in order to avoid bleeding in the peri-cardioversion period. COULD YOU GIVE US AN OVERVIEW OF THE ENSURE-AF AND EMANATE TRIALS? 00:48 – The ENSURE-AF is a really interesting trial. In fact it’s designed to enroll over 2,000 patients, 2,200 patients. So it will be the largest cardioversion trial with the use of a novel agent. And it will be comparing the use of warfarin plus enoxaparin, versus a new agent, edoxaban. So this trial will produce results about the convenience of this new treatment in terms of easy to use and also efficacy and safety. WHAT ARE THE OTHER LIMITATIONS OF CURRENTLY AVAILABLE NEW ORAL ANTICOAGULANTS? 01:32 – Limitations of the novel agents are few compared to what was the case with warfarin. There are a few limitations but still there are some. For example, interaction with other drugs that can be used in the setting of cardioversion, like for example, drohedarone. Drohedarone is contraindicated when you are using dabigatran, that is one of these novel agents. And there are limited information about the use in combination of drohedarone with other novel agents. We have in fact recently reported a short series of the use of rivaroxaban and drohedarone, and apparently it’s safe. Apart from this limitation, there are few other interactions. So I think that most of these drugs are really safe. WHAT FUTURE STUDIES ARE PLANNED FOR NEW ORAL ANTICOAGULANTS? 02:26 – These are exciting new drugs. So originally they were tested in the setting of the general AF population. However, once the efficacy of this drug and safety profile of them have been proven, now the new trials are trying to expand the field of treatment for over subpopulations. Like for example those patients who are undergoing PCI or patients with a suspicion of underlying atrial fibrillation, like for example patients having a cryptogenic stroke.
Joachim Ehrlich (JW Goethe University, Frankfurt) talks about the second-generation balloons used in single-shot cryoablation techniques and their efficacy over older technologies in atrial fibrillation. He also discusses the advantages of cryoablation over radiofrequency ablation; although, as the FIRE AND ICE trial showed, efficacy is similar between both techniques, cryoablation is easier to use and quicker in treating patients with paroxysmal atrial fibrillation. With the new-generation cryoballoon catheter, the speed of the procedure overall is quicker and success can be monitored online. Dr Ehrlich predicts that, due to the simplicity and ease of the cryoablation procedure, many physicians will be able to treat their patients with this technique. Filmed at EHRA 2018, Barcelona. Questions: 1. Please can you describe any recent progress that has been made in single-shot cryoablation techniques? 0:07 2. What are the advantages of cryoablation over radiofrequency ablation and how do they differ in terms of efficacy? 0:36 3. How do the features of the new-generation cryoballoon catheter contribute to its ease of use? 1:07 4. What are the clinical implications of cryoablation and what is the impact on patient outcomes in the real world? 1:34

Atrial fibrillation: Latest Videos

Video List based on Category on Node Page

Latest Videos

Tom De Potter (OLV Hospital, Aalst) discusses the aims of recent trials on ultra-low-temperature continuous ablation and summarises the results, which showed that the system is highly efficacious in an acute setting. Although long-term outcomes are yet to be determined, the results so far show...
Joachim Ehrlich (JW Goethe University, Frankfurt) talks about the second-generation balloons used in single-shot cryoablation techniques and their efficacy over older technologies in atrial fibrillation. He also discusses the advantages of cryoablation over radiofrequency ablation; although, as...
Jose Merino (Hospital General Universitario La Paz, Madrid) discusses recent advances in technology to improve complex ablation success rates for atrial fibrillation (AF) and/or ventricular tachycardia (VT), including new imaging techniques, and unmet needs relating to complex ablation for AF/VT,...
Marco Proietti (Institute of Cardiovascular Sciences, University of Birmingham, Birmingham) discusses the SPORTIF Trials and their aim to investigate and compare ximelagatran, the first non-vitamin K antagonist oral anticoagulant, with warfarin in patients with atrial fibrillation. The trial was...
Jelena Kornej (Heart Centre, University of Leipzig, Saxony) discusses the LIFE-Adult-Study, a population-based cohort study including 10,000 participants from Leipzig and eastern Germany. The study was initiated and conducted by the Leipzig Research Centre for Civilisation Diseases (LIFE), and the...
Dipak Kotecha (Institute of Cardiovascular Sciences, University of Birmingham) discusses the FAST trial - the first long-term follow-up of a randomised trial comparing thoracoscopic surgical atrial fibrillation ablation with catheter ablation with the aim of rhythm control. Thoracoscopic ablation...

LATEST TWEETS

Conference Highlights